Long-term symptoms more common after Lyme disease More than a quarter of people with Lyme disease continue to have long-term symptoms that lead to limitations in daily life even after treatment.
COVID-19 consequences impact vulnerable groups more in the long term The effects of the corona crisis have a greater impact on vulnerable groups in society, such as lower-educated adults, young people, the elderly and people with underlying health problems.
Spread of tick-borne encephalitis virus in the Netherlands Every year about 1.5 million ticks bite someone in the Netherlands, especially between March and October. Most people will not get sick of that.
Tick found in Drenthe is a Hyalomma tick RIVM has investigated the so-called giant tick that was found in Odoorn in the province of Drenthe on 13 July. It is a Hyalomma marginatum female.
If you have found a tick bite, check for others! One in five people who report having been bitten by a tick on Tekenrader.nl report that they have more than one tick bite. If you have found one tick bite, check for others!
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).
Lyme disease cases have quadrupled According to a survey by RIVM , 27,000 people were infected with Lyme disease in 2017. In 2014, the last time RIVM reported on the incidence of tick-borne disease, this number was 25,000.
First products Dutch Public Health Foresight study available in English In 2017, RIVM launched a Trend Scenario, as well as three thematic reports about the future demand for health care, technology and wider determinants of health.
Trend scenario PHF- 2018 identifies societal challenges for the future If historical trends continue unchanged, dementia will be the leading cause of disease burden in 2040 and the main cause of death.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.